Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium
To resolve the ongoing controversy surrounding the impact of teratoma (TER) in the primary among patients with metastatic testicular non-seminomatous germ-cell tumours (NSGCT). Using the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium database, we compared the survival...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2024-05, Vol.202, p.114042-114042, Article 114042 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114042 |
|---|---|
| container_issue | |
| container_start_page | 114042 |
| container_title | European journal of cancer (1990) |
| container_volume | 202 |
| creator | Bührer, Emanuel D'Haese, David Daugaard, Gedske de Wit, Ronald Albany, Costantine Tryakin, Alexey Fizazi, Karim Stahl, Olof Gietema, Jourik A. De Giorgi, Ugo Cafferty, Fay H. Hansen, Aaron R. Tandstad, Torgrim Huddart, Robert A. Necchi, Andrea Sweeney, Christopher J. Garcia-Del-Muro, Xavier Heng, Daniel Y.C. Lorch, Anja Chovanec, Michal Winquist, Eric Grimison, Peter Feldman, Darren R. Terbuch, Angelika Hentrich, Marcus Bokemeyer, Carsten Negaard, Helene Fankhauser, Christian Shamash, Jonathan Vaughn, David J. Sternberg, Cora N. Heidenreich, Axel Collette, Laurence Gillessen, Silke Beyer, Jörg |
| description | To resolve the ongoing controversy surrounding the impact of teratoma (TER) in the primary among patients with metastatic testicular non-seminomatous germ-cell tumours (NSGCT).
Using the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium database, we compared the survival probabilities of patients with metastatic testicular GCT with TER (TER) or without TER (NTER) in their primaries corrected for known prognostic factors. Progression-free survival (5y-PFS) and overall survival at 5 years (5y-OS) were estimated by the Kaplan-Meier method.
Among 6792 patients with metastatic testicular NSGCT, 3224 (47%) had TER in their primary, and 3568 (53%) did not. In the IGCCCG good prognosis group, the 5y-PFS was 87.8% in TER versus 92.0% in NTER patients (p = 0.0001), the respective 5y-OS were 94.5% versus 96.5% (p = 0.0032). The corresponding figures in the intermediate prognosis group were 5y-PFS 76.9% versus 81.6% (p = 0.0432) in TER and NTER and 5y-OS 90.4% versus 90.9% (p = 0.8514), respectively. In the poor prognosis group, there was no difference, neither in 5y-PFS [54.3% in TER patients versus 55.4% (p = 0.7472) in NTER], nor in 5y-OS [69.4% versus 67.7% (p = 0.3841)]. NSGCT patients with TER had more residual masses (65.3% versus 51.7%, p |
| doi_str_mv | 10.1016/j.ejca.2024.114042 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3031660990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804924006981</els_id><sourcerecordid>3031660990</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-76ee4d1be6658185416166b5be551e707bcd5c4aa4ddbf60aa9acef7a80a83f53</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhS0EotvCH-CAfOSSxU7sxEFcUATblSohIXq2Js6EehXHwXa24ofwf3G0hSMnj6zvPc2bR8gbzvac8fr9aY8nA_uSlWLPuWCifEZ2XDVtwZQsn5Mda2VbKCbaK3Id44kx1ijBXpKrSslatGWzI7-PbgGTqB9pwgDJO6B-pnENZ3uGiS7B99DbySaLcaMWyNOcIn206YE6TBBT_jJ09nMR0dk5WyS_RvoDg6MGp4kamA2GD_QbxnXK0jF4R9MD0uOh67oDvV8GSEg7P0cfkl3dK_JihCni66f3htx_-fy9uy3uvh6O3ae7wlSsSUVTI4qB91jXUnElBa95XfeyRyk5NqzpzSCNABDD0I81A2jB4NiAYqCqUVY35N3FN8f8uWJM2tm4rQwz5gi6YlU2ZG3LMlpeUBN8jAFHvQTrIPzSnOmtDn3SWx16q0Nf6siit0_-a-9w-Cf5e_8MfLwAmFOeLQYdTT6vwcEGNEkP3v7P_w-8LJ6-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3031660990</pqid></control><display><type>article</type><title>Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium</title><source>Elsevier ScienceDirect Journals</source><creator>Bührer, Emanuel ; D'Haese, David ; Daugaard, Gedske ; de Wit, Ronald ; Albany, Costantine ; Tryakin, Alexey ; Fizazi, Karim ; Stahl, Olof ; Gietema, Jourik A. ; De Giorgi, Ugo ; Cafferty, Fay H. ; Hansen, Aaron R. ; Tandstad, Torgrim ; Huddart, Robert A. ; Necchi, Andrea ; Sweeney, Christopher J. ; Garcia-Del-Muro, Xavier ; Heng, Daniel Y.C. ; Lorch, Anja ; Chovanec, Michal ; Winquist, Eric ; Grimison, Peter ; Feldman, Darren R. ; Terbuch, Angelika ; Hentrich, Marcus ; Bokemeyer, Carsten ; Negaard, Helene ; Fankhauser, Christian ; Shamash, Jonathan ; Vaughn, David J. ; Sternberg, Cora N. ; Heidenreich, Axel ; Collette, Laurence ; Gillessen, Silke ; Beyer, Jörg</creator><creatorcontrib>Bührer, Emanuel ; D'Haese, David ; Daugaard, Gedske ; de Wit, Ronald ; Albany, Costantine ; Tryakin, Alexey ; Fizazi, Karim ; Stahl, Olof ; Gietema, Jourik A. ; De Giorgi, Ugo ; Cafferty, Fay H. ; Hansen, Aaron R. ; Tandstad, Torgrim ; Huddart, Robert A. ; Necchi, Andrea ; Sweeney, Christopher J. ; Garcia-Del-Muro, Xavier ; Heng, Daniel Y.C. ; Lorch, Anja ; Chovanec, Michal ; Winquist, Eric ; Grimison, Peter ; Feldman, Darren R. ; Terbuch, Angelika ; Hentrich, Marcus ; Bokemeyer, Carsten ; Negaard, Helene ; Fankhauser, Christian ; Shamash, Jonathan ; Vaughn, David J. ; Sternberg, Cora N. ; Heidenreich, Axel ; Collette, Laurence ; Gillessen, Silke ; Beyer, Jörg</creatorcontrib><description>To resolve the ongoing controversy surrounding the impact of teratoma (TER) in the primary among patients with metastatic testicular non-seminomatous germ-cell tumours (NSGCT).
Using the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium database, we compared the survival probabilities of patients with metastatic testicular GCT with TER (TER) or without TER (NTER) in their primaries corrected for known prognostic factors. Progression-free survival (5y-PFS) and overall survival at 5 years (5y-OS) were estimated by the Kaplan-Meier method.
Among 6792 patients with metastatic testicular NSGCT, 3224 (47%) had TER in their primary, and 3568 (53%) did not. In the IGCCCG good prognosis group, the 5y-PFS was 87.8% in TER versus 92.0% in NTER patients (p = 0.0001), the respective 5y-OS were 94.5% versus 96.5% (p = 0.0032). The corresponding figures in the intermediate prognosis group were 5y-PFS 76.9% versus 81.6% (p = 0.0432) in TER and NTER and 5y-OS 90.4% versus 90.9% (p = 0.8514), respectively. In the poor prognosis group, there was no difference, neither in 5y-PFS [54.3% in TER patients versus 55.4% (p = 0.7472) in NTER], nor in 5y-OS [69.4% versus 67.7% (p = 0.3841)]. NSGCT patients with TER had more residual masses (65.3% versus 51.7%, p < 0.0001), and therefore received post-chemotherapy surgery more frequently than NTER patients (46.8% versus 32.0%, p < 0.0001).
Teratoma in the primary tumour of patients with metastatic NSGCT negatively impacts on survival in the good and intermediate, but not in the poor IGCCCG prognostic groups.
•Teratoma negatively impacts 5y-OS in IGCCCG good prognosis patients.•Teratoma negatively impacts 5y-PFS in IGCCCG intermediate prognosis patients.•Teratoma does not impact survival in IGCCCG poor prognosis patients.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2024.114042</identifier><identifier>PMID: 38564927</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Germ-cell tumours ; IGCCCG ; Non-seminoma ; Prognosis ; Teratoma</subject><ispartof>European journal of cancer (1990), 2024-05, Vol.202, p.114042-114042, Article 114042</ispartof><rights>2024</rights><rights>Copyright © 2024. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-76ee4d1be6658185416166b5be551e707bcd5c4aa4ddbf60aa9acef7a80a83f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejca.2024.114042$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38564927$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bührer, Emanuel</creatorcontrib><creatorcontrib>D'Haese, David</creatorcontrib><creatorcontrib>Daugaard, Gedske</creatorcontrib><creatorcontrib>de Wit, Ronald</creatorcontrib><creatorcontrib>Albany, Costantine</creatorcontrib><creatorcontrib>Tryakin, Alexey</creatorcontrib><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>Stahl, Olof</creatorcontrib><creatorcontrib>Gietema, Jourik A.</creatorcontrib><creatorcontrib>De Giorgi, Ugo</creatorcontrib><creatorcontrib>Cafferty, Fay H.</creatorcontrib><creatorcontrib>Hansen, Aaron R.</creatorcontrib><creatorcontrib>Tandstad, Torgrim</creatorcontrib><creatorcontrib>Huddart, Robert A.</creatorcontrib><creatorcontrib>Necchi, Andrea</creatorcontrib><creatorcontrib>Sweeney, Christopher J.</creatorcontrib><creatorcontrib>Garcia-Del-Muro, Xavier</creatorcontrib><creatorcontrib>Heng, Daniel Y.C.</creatorcontrib><creatorcontrib>Lorch, Anja</creatorcontrib><creatorcontrib>Chovanec, Michal</creatorcontrib><creatorcontrib>Winquist, Eric</creatorcontrib><creatorcontrib>Grimison, Peter</creatorcontrib><creatorcontrib>Feldman, Darren R.</creatorcontrib><creatorcontrib>Terbuch, Angelika</creatorcontrib><creatorcontrib>Hentrich, Marcus</creatorcontrib><creatorcontrib>Bokemeyer, Carsten</creatorcontrib><creatorcontrib>Negaard, Helene</creatorcontrib><creatorcontrib>Fankhauser, Christian</creatorcontrib><creatorcontrib>Shamash, Jonathan</creatorcontrib><creatorcontrib>Vaughn, David J.</creatorcontrib><creatorcontrib>Sternberg, Cora N.</creatorcontrib><creatorcontrib>Heidenreich, Axel</creatorcontrib><creatorcontrib>Collette, Laurence</creatorcontrib><creatorcontrib>Gillessen, Silke</creatorcontrib><creatorcontrib>Beyer, Jörg</creatorcontrib><title>Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>To resolve the ongoing controversy surrounding the impact of teratoma (TER) in the primary among patients with metastatic testicular non-seminomatous germ-cell tumours (NSGCT).
Using the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium database, we compared the survival probabilities of patients with metastatic testicular GCT with TER (TER) or without TER (NTER) in their primaries corrected for known prognostic factors. Progression-free survival (5y-PFS) and overall survival at 5 years (5y-OS) were estimated by the Kaplan-Meier method.
Among 6792 patients with metastatic testicular NSGCT, 3224 (47%) had TER in their primary, and 3568 (53%) did not. In the IGCCCG good prognosis group, the 5y-PFS was 87.8% in TER versus 92.0% in NTER patients (p = 0.0001), the respective 5y-OS were 94.5% versus 96.5% (p = 0.0032). The corresponding figures in the intermediate prognosis group were 5y-PFS 76.9% versus 81.6% (p = 0.0432) in TER and NTER and 5y-OS 90.4% versus 90.9% (p = 0.8514), respectively. In the poor prognosis group, there was no difference, neither in 5y-PFS [54.3% in TER patients versus 55.4% (p = 0.7472) in NTER], nor in 5y-OS [69.4% versus 67.7% (p = 0.3841)]. NSGCT patients with TER had more residual masses (65.3% versus 51.7%, p < 0.0001), and therefore received post-chemotherapy surgery more frequently than NTER patients (46.8% versus 32.0%, p < 0.0001).
Teratoma in the primary tumour of patients with metastatic NSGCT negatively impacts on survival in the good and intermediate, but not in the poor IGCCCG prognostic groups.
•Teratoma negatively impacts 5y-OS in IGCCCG good prognosis patients.•Teratoma negatively impacts 5y-PFS in IGCCCG intermediate prognosis patients.•Teratoma does not impact survival in IGCCCG poor prognosis patients.</description><subject>Germ-cell tumours</subject><subject>IGCCCG</subject><subject>Non-seminoma</subject><subject>Prognosis</subject><subject>Teratoma</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kUFv1DAQhS0EotvCH-CAfOSSxU7sxEFcUATblSohIXq2Js6EehXHwXa24ofwf3G0hSMnj6zvPc2bR8gbzvac8fr9aY8nA_uSlWLPuWCifEZ2XDVtwZQsn5Mda2VbKCbaK3Id44kx1ijBXpKrSslatGWzI7-PbgGTqB9pwgDJO6B-pnENZ3uGiS7B99DbySaLcaMWyNOcIn206YE6TBBT_jJ09nMR0dk5WyS_RvoDg6MGp4kamA2GD_QbxnXK0jF4R9MD0uOh67oDvV8GSEg7P0cfkl3dK_JihCni66f3htx_-fy9uy3uvh6O3ae7wlSsSUVTI4qB91jXUnElBa95XfeyRyk5NqzpzSCNABDD0I81A2jB4NiAYqCqUVY35N3FN8f8uWJM2tm4rQwz5gi6YlU2ZG3LMlpeUBN8jAFHvQTrIPzSnOmtDn3SWx16q0Nf6siit0_-a-9w-Cf5e_8MfLwAmFOeLQYdTT6vwcEGNEkP3v7P_w-8LJ6-</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Bührer, Emanuel</creator><creator>D'Haese, David</creator><creator>Daugaard, Gedske</creator><creator>de Wit, Ronald</creator><creator>Albany, Costantine</creator><creator>Tryakin, Alexey</creator><creator>Fizazi, Karim</creator><creator>Stahl, Olof</creator><creator>Gietema, Jourik A.</creator><creator>De Giorgi, Ugo</creator><creator>Cafferty, Fay H.</creator><creator>Hansen, Aaron R.</creator><creator>Tandstad, Torgrim</creator><creator>Huddart, Robert A.</creator><creator>Necchi, Andrea</creator><creator>Sweeney, Christopher J.</creator><creator>Garcia-Del-Muro, Xavier</creator><creator>Heng, Daniel Y.C.</creator><creator>Lorch, Anja</creator><creator>Chovanec, Michal</creator><creator>Winquist, Eric</creator><creator>Grimison, Peter</creator><creator>Feldman, Darren R.</creator><creator>Terbuch, Angelika</creator><creator>Hentrich, Marcus</creator><creator>Bokemeyer, Carsten</creator><creator>Negaard, Helene</creator><creator>Fankhauser, Christian</creator><creator>Shamash, Jonathan</creator><creator>Vaughn, David J.</creator><creator>Sternberg, Cora N.</creator><creator>Heidenreich, Axel</creator><creator>Collette, Laurence</creator><creator>Gillessen, Silke</creator><creator>Beyer, Jörg</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240501</creationdate><title>Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium</title><author>Bührer, Emanuel ; D'Haese, David ; Daugaard, Gedske ; de Wit, Ronald ; Albany, Costantine ; Tryakin, Alexey ; Fizazi, Karim ; Stahl, Olof ; Gietema, Jourik A. ; De Giorgi, Ugo ; Cafferty, Fay H. ; Hansen, Aaron R. ; Tandstad, Torgrim ; Huddart, Robert A. ; Necchi, Andrea ; Sweeney, Christopher J. ; Garcia-Del-Muro, Xavier ; Heng, Daniel Y.C. ; Lorch, Anja ; Chovanec, Michal ; Winquist, Eric ; Grimison, Peter ; Feldman, Darren R. ; Terbuch, Angelika ; Hentrich, Marcus ; Bokemeyer, Carsten ; Negaard, Helene ; Fankhauser, Christian ; Shamash, Jonathan ; Vaughn, David J. ; Sternberg, Cora N. ; Heidenreich, Axel ; Collette, Laurence ; Gillessen, Silke ; Beyer, Jörg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-76ee4d1be6658185416166b5be551e707bcd5c4aa4ddbf60aa9acef7a80a83f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Germ-cell tumours</topic><topic>IGCCCG</topic><topic>Non-seminoma</topic><topic>Prognosis</topic><topic>Teratoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bührer, Emanuel</creatorcontrib><creatorcontrib>D'Haese, David</creatorcontrib><creatorcontrib>Daugaard, Gedske</creatorcontrib><creatorcontrib>de Wit, Ronald</creatorcontrib><creatorcontrib>Albany, Costantine</creatorcontrib><creatorcontrib>Tryakin, Alexey</creatorcontrib><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>Stahl, Olof</creatorcontrib><creatorcontrib>Gietema, Jourik A.</creatorcontrib><creatorcontrib>De Giorgi, Ugo</creatorcontrib><creatorcontrib>Cafferty, Fay H.</creatorcontrib><creatorcontrib>Hansen, Aaron R.</creatorcontrib><creatorcontrib>Tandstad, Torgrim</creatorcontrib><creatorcontrib>Huddart, Robert A.</creatorcontrib><creatorcontrib>Necchi, Andrea</creatorcontrib><creatorcontrib>Sweeney, Christopher J.</creatorcontrib><creatorcontrib>Garcia-Del-Muro, Xavier</creatorcontrib><creatorcontrib>Heng, Daniel Y.C.</creatorcontrib><creatorcontrib>Lorch, Anja</creatorcontrib><creatorcontrib>Chovanec, Michal</creatorcontrib><creatorcontrib>Winquist, Eric</creatorcontrib><creatorcontrib>Grimison, Peter</creatorcontrib><creatorcontrib>Feldman, Darren R.</creatorcontrib><creatorcontrib>Terbuch, Angelika</creatorcontrib><creatorcontrib>Hentrich, Marcus</creatorcontrib><creatorcontrib>Bokemeyer, Carsten</creatorcontrib><creatorcontrib>Negaard, Helene</creatorcontrib><creatorcontrib>Fankhauser, Christian</creatorcontrib><creatorcontrib>Shamash, Jonathan</creatorcontrib><creatorcontrib>Vaughn, David J.</creatorcontrib><creatorcontrib>Sternberg, Cora N.</creatorcontrib><creatorcontrib>Heidenreich, Axel</creatorcontrib><creatorcontrib>Collette, Laurence</creatorcontrib><creatorcontrib>Gillessen, Silke</creatorcontrib><creatorcontrib>Beyer, Jörg</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bührer, Emanuel</au><au>D'Haese, David</au><au>Daugaard, Gedske</au><au>de Wit, Ronald</au><au>Albany, Costantine</au><au>Tryakin, Alexey</au><au>Fizazi, Karim</au><au>Stahl, Olof</au><au>Gietema, Jourik A.</au><au>De Giorgi, Ugo</au><au>Cafferty, Fay H.</au><au>Hansen, Aaron R.</au><au>Tandstad, Torgrim</au><au>Huddart, Robert A.</au><au>Necchi, Andrea</au><au>Sweeney, Christopher J.</au><au>Garcia-Del-Muro, Xavier</au><au>Heng, Daniel Y.C.</au><au>Lorch, Anja</au><au>Chovanec, Michal</au><au>Winquist, Eric</au><au>Grimison, Peter</au><au>Feldman, Darren R.</au><au>Terbuch, Angelika</au><au>Hentrich, Marcus</au><au>Bokemeyer, Carsten</au><au>Negaard, Helene</au><au>Fankhauser, Christian</au><au>Shamash, Jonathan</au><au>Vaughn, David J.</au><au>Sternberg, Cora N.</au><au>Heidenreich, Axel</au><au>Collette, Laurence</au><au>Gillessen, Silke</au><au>Beyer, Jörg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>202</volume><spage>114042</spage><epage>114042</epage><pages>114042-114042</pages><artnum>114042</artnum><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>To resolve the ongoing controversy surrounding the impact of teratoma (TER) in the primary among patients with metastatic testicular non-seminomatous germ-cell tumours (NSGCT).
Using the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium database, we compared the survival probabilities of patients with metastatic testicular GCT with TER (TER) or without TER (NTER) in their primaries corrected for known prognostic factors. Progression-free survival (5y-PFS) and overall survival at 5 years (5y-OS) were estimated by the Kaplan-Meier method.
Among 6792 patients with metastatic testicular NSGCT, 3224 (47%) had TER in their primary, and 3568 (53%) did not. In the IGCCCG good prognosis group, the 5y-PFS was 87.8% in TER versus 92.0% in NTER patients (p = 0.0001), the respective 5y-OS were 94.5% versus 96.5% (p = 0.0032). The corresponding figures in the intermediate prognosis group were 5y-PFS 76.9% versus 81.6% (p = 0.0432) in TER and NTER and 5y-OS 90.4% versus 90.9% (p = 0.8514), respectively. In the poor prognosis group, there was no difference, neither in 5y-PFS [54.3% in TER patients versus 55.4% (p = 0.7472) in NTER], nor in 5y-OS [69.4% versus 67.7% (p = 0.3841)]. NSGCT patients with TER had more residual masses (65.3% versus 51.7%, p < 0.0001), and therefore received post-chemotherapy surgery more frequently than NTER patients (46.8% versus 32.0%, p < 0.0001).
Teratoma in the primary tumour of patients with metastatic NSGCT negatively impacts on survival in the good and intermediate, but not in the poor IGCCCG prognostic groups.
•Teratoma negatively impacts 5y-OS in IGCCCG good prognosis patients.•Teratoma negatively impacts 5y-PFS in IGCCCG intermediate prognosis patients.•Teratoma does not impact survival in IGCCCG poor prognosis patients.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>38564927</pmid><doi>10.1016/j.ejca.2024.114042</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2024-05, Vol.202, p.114042-114042, Article 114042 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3031660990 |
| source | Elsevier ScienceDirect Journals |
| subjects | Germ-cell tumours IGCCCG Non-seminoma Prognosis Teratoma |
| title | Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T03%3A55%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20teratoma%20on%20survival%20probabilities%20of%20patients%20with%20metastatic%20non-seminomatous%20germ%20cell%20cancer:%20Results%20from%20the%20IGCCCG%20Update%20Consortium&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=B%C3%BChrer,%20Emanuel&rft.date=2024-05-01&rft.volume=202&rft.spage=114042&rft.epage=114042&rft.pages=114042-114042&rft.artnum=114042&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2024.114042&rft_dat=%3Cproquest_cross%3E3031660990%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3031660990&rft_id=info:pmid/38564927&rft_els_id=S0959804924006981&rfr_iscdi=true |